Atenolol (CAS 29122-68-7) is a cardioselective β₁-adrenergic receptor blocker widely used as an active pharmaceutical ingredient in cardiovascular therapy. It reduces heart rate, cardiac output and myocardial oxygen demand, making it suitable for treating hypertension, angina pectoris and certain arrhythmias. As a well-established beta-blocker with a long history of clinical use, Atenolol remains an important option in many treatment guidelines worldwide.
Atenolol (29122-68-7) from TCS GROUP is offered as a high-purity API with robust quality control and regulatory documentation support. Its pharmacokinetic profile—moderate bioavailability, limited metabolism, and renal excretion—makes dosing relatively predictable. The drug is commonly formulated into oral tablets and sometimes into injectable forms, with strengths tailored to individual patient needs.
From a formulation standpoint, Atenolol exhibits good chemical stability but has modest aqueous solubility, which must be considered when designing dosage forms. Optimizing particle size distribution and choosing the right excipient system are critical to achieving uniform content and dissolution characteristics. Many manufacturers rely on proven direct-compression systems: for example, pairing Atenolol with Microcrystalline Cellulose – Premium Filler & Binder for Direct Compression ensures robust tablet hardness, low friability and consistent performance.
In more complex cardiovascular portfolios, Atenolol is often discussed alongside other APIs supplied by TCS GROUP. Anti-arrhythmic agents such as Amiodarone Hydrochloride (19774-82-4) and ACE inhibitors like Benazepril (86541-75-5) broaden the therapeutic spectrum, allowing companies to build comprehensive cardiovascular product lines. By sourcing multiple APIs from the same partner, formulators can simplify supplier management, align quality systems and accelerate project timelines.
TCS GROUP supports customers not only with high-quality Atenolol API, but also with technical insights on processing, compatibility and stability. This partnership approach helps generic manufacturers and brand owners alike to develop reliable, cost-effective cardiovascular medicines that meet regulatory requirements and patient expectations.